Beam Therapeutics (BEAM) Debt to Equity: 2019-2025
Historic Debt to Equity for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $0.01.
- Beam Therapeutics' Debt to Equity fell 36.61% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year decrease of 36.61%. This contributed to the annual value of $0.01 for FY2024, which is 4.05% up from last year.
- As of Q3 2025, Beam Therapeutics' Debt to Equity stood at $0.01, which was up 80.61% from $0.00 recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Debt to Equity ranged from a high of $0.17 in Q1 2021 and a low of $0.00 during Q2 2025.
- Its 3-year average for Debt to Equity is $0.01, with a median of $0.01 in 2023.
- Per our database at Business Quant, Beam Therapeutics' Debt to Equity surged by 330.79% in 2021 and then plummeted by 86.83% in 2022.
- Over the past 5 years, Beam Therapeutics' Debt to Equity (Quarterly) stood at $0.05 in 2021, then tumbled by 51.12% to $0.02 in 2022, then crashed by 55.89% to $0.01 in 2023, then climbed by 4.05% to $0.01 in 2024, then tumbled by 36.61% to $0.01 in 2025.
- Its Debt to Equity was $0.01 in Q3 2025, compared to $0.00 in Q2 2025 and $0.00 in Q1 2025.